Regeneron Pharmaceuticals, Inc.

University Health Network

Fio Corporation

Kevin Kain

Sarah J Higgins

Lisa Arleen Purcell Ngambo

Lisa A Purcell

W Conrad Liles

Laura Erdman

Andrea Conroy

The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and/or life threatening response to illness and/or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and/or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and/or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and/or monitor the effectiveness of treatment interventions for an individual who has a critical illness.

Biomarkers for early determination of a critical or life threatening response to illness and/or treatment response

The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.

Angiopoietin-based interventions for treating cerebral malaria

Growing community of inventors

Toronto, Canada

Kevin Kain